Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934




Download 2.75 Mb.
NameRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934
page65/65
A typeDocumentation
1   ...   57   58   59   60   61   62   63   64   65

Exhibit 12.2

 

Certification by the Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Smital Shah, certify that:

 

1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

Date: March 30, 2018

 

By:

/S/ Smital Shah

 

 

Name:

Smital Shah

 

 

Title:

Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

 





Exhibit 13.1

 

Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Annual Report on Form 20-F of ProQR Therapeutics N.V. (the “Company”) for the year ended December 31, 2017, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Daniel de Boer, as Chief Executive Officer of the Company, and Smital Shah, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 30, 2018

 

By:

/S/ Daniel de Boer

 

 

Name:

Daniel de Boer

 

 

Title:

Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

 

 

 

By:

/S/ Smital Shah

 

 

Name:

Smital Shah

 

 

Title:

Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

 





Exhibit 15.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To: the Supervisory Board and Shareholders of ProQR Therapeutics N.V.

 

We consent to the incorporation by reference in the Registration Statement No. 333-199451 on Form S-8 and No. 333-207245 on Form F-3 of our report dated March 30, 2018 relating to the consolidated financial statements of ProQR Therapeutics N.V. appearing in this Annual Report on Form 20-F of ProQR Therapeutics N.V. for the year ended December 31, 2017.

 

 

/s/Deloitte Accountants B.V.

 

Amsterdam, the Netherlands

March 30, 2018

 
1   ...   57   58   59   60   61   62   63   64   65

Related:

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or 12(g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or 12(g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconX registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 icon[ ] registration statement pursuant to section 12(b) or (g) of the...

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconO Registration statement pursuant to Section 12(b) or 12(g) of the...

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or 12(g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or 12(g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconO registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconO registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or 12(g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934

Registration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934 iconRegistration statement pursuant to section 12(b) or (g) of the securities exchange act of 1934




manual




When copying material provide a link © 2017
contacts
manual-guide.com
search